Simoctocog alfa

Drug Profile

Simoctocog alfa

Alternative Names: Factor VIII - Octapharma; Human-cl rhFVIII - Octapharma; Nuwiq

Latest Information Update: 07 Jun 2017

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Octapharma
  • Developer Cardinal Health; Octapharma
  • Class Antihaemorrhagics; Blood coagulation factors; Coagulants; Recombinant fusion proteins; Recombinant proteins
  • Mechanism of Action Blood coagulation factor replacements; Factor X stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Haemophilia A

Most Recent Events

  • 22 May 2017 Additional pharmacokinetics data from the phase IIIb NuPreviq trial in Haemophilia A released by Octapharma
  • 19 Apr 2017 Octapharma completes the NuProtect trial in Haemophilia A (Treatment-naive) in Belarus, Canada, France, Georgia, Germany, India, Italy, Moldova, Morocco, Poland, Portugal, Russia, Slovenia, Spain, Ukraine, United Kingdom and USA (NCT01712438)
  • 21 Dec 2016 Interim immunogenicity data from the phase III NuProtect presented at the 58th Annual Meeting and Exposition of the American Society of Hematology (ASH-Hem-2016)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top